GlassScriptPhysician profile
Erol M Kosar
NPI 1104820927
$23,786.43
in general payments reported to CMS, 2019-2025
35 companies · $6,099 in 2025
The $6,099 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,056 · 2020: $1,449 · 2021: $4,436 · 2022: $1,100 · 2023: $1,759 · 2024: $2,890 · 2025: $6,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,180 · Travel and Lodging: $3,317 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,180.22 |
| Travel and Lodging | $3,316.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $8,614.00 | 2019-2025 | Bodyguardian, Farapulse, Watchman Flx |
| Medtronic, INC. | $6,410.09 | 2021-2025 | Micra, Pulseselect, Pulseselect |
| Abbott Laboratories | $2,543.83 | 2019-2024 | Aveir, Navitor |
| Medical Device Business Services, INC. | $736.39 | 2019 | |
| Biosense Webster, INC. | $687.08 | 2019-2024 | Carto 3 |
| Novartis Pharmaceuticals Corporation | $680.50 | 2019-2025 | |
| Pfizer INC. | $654.72 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $484.43 | 2019-2023 | Xarelto |
| Cardiva Medical, INC. | $401.35 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Medtronic Vascular, INC. | $379.56 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $266.88 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $209.14 | 2019-2024 | |
| Amgen INC. | $170.62 | 2019-2025 | Repatha |
| Impulse Dynamics (USA) INC. | $166.96 | 2023 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $161.16 | 2022-2025 | Camzyos, Eliquis |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acutus Medical, INC. | $140.64 | 2023 | |
| Novo Nordisk INC | $138.08 | 2021-2023 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $135.52 | 2019-2024 | Farxiga |
| Cvrx, INC. | $101.74 | 2024-2025 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $97.73 | 2023-2025 | Assure Wcd |
| Biotronik INC. | $91.24 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $72.72 | 2023-2025 | Verquvo, Capvaxive |
| Philips North America LLC | $69.04 | 2024 | (Bs2) Lm Undivided |
| Akcea Therapeutics, INC. | $65.59 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.83 | 2023-2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $42.90 | 2020-2024 | Amvuttra |
| Altathera Pharmaceuticals LLC | $29.54 | 2025 | Sotalol Hydrochloride |
| Actelion Pharmaceuticals US, INC. | $28.75 | 2023 | Opsumit, Uptravi |
| Heartflow, INC. | $28.07 | 2025 | |
| Inspire Medical Systems, INC. | $26.83 | 2025 | Inspire |
| Atricure, INC. | $21.51 | 2021 | |
| Esperion Therapeutics, INC. | $21.21 | 2024 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $19.94 | 2024 | Arcalyst |
| Bardy Diagnostics, INC. | $15.86 | 2021 | |
| Ethicon US, LLC | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erol Kosar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.